Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 3/2006

01.06.2006

Comparison of Fusion Imaging Using a Combined SPECT/CT System and Intra-arterial CT: Assessment of Drug Distribution by an Implantable Port System in Patients Undergoing Hepatic Arterial Infusion Chemotherapy

verfasst von: Osamu Ikeda, Shinichiroh Kusunoki, Takeshi Nakaura, Shinya Shiraishi, Kouichi Kawanaka, Seiji Tomiguchi, Yasuyuki Yamashita, Hiroshi Takamori, Akira Chikamoto, Keiichiro Kanemitsu

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Hepatic arterial infusion (HAI) chemotherapy is effective for treating primary and metastatic carcinoma of the liver. We compared the perfusion patterns of HAI chemotherapy on intra-arterial port-catheter computed tomography (iapc-CT) and fused images obtained with a combined single-photon emission computed tomography/computed tomography (SPECT/CT) system. We studied 28 patients with primary or metastatic carcinoma of the liver who bore an implantable HAI port system. All underwent abdominal SPECT using Tc-99m-MAA (185 Mbq); the injection rate was 1 mL/min, identical to the chemotherapy infusion rate, and 0.5 mL/sec for iapc-CT. Delivery was through an implantable port. We compared the intrahepatic perfusion (IHP) and extrahepatic perfusion (EHP) patterns of HAI chemotherapy on iapc-CT images and fused images obtained with a combined SPECT/CT system. In 23 of 28 patients (82%), IHP patterns on iapc-CT images and fused images were identical. In 5 of the 28 patients (18%), IHP on fusion images was different from IHP on iapc-CT images. EHP was seen on fused images in 12 of the 28 patients (43%) and on iapc-CT images in 8 patients (29%). In 17 patients (61%), upper gastrointestinal endoscopy revealed gastroduodenal mucosal lesions. EHP was revealed on fused images in 10 of these patients; 9 of them manifested gastroduodenal toxicity at the time of subsequent HAI chemotherapy. Fusion imaging using the combined SPECT/CT system reflects the actual distribution of the infused anticancer agent. This information is valuable not only for monitoring adequate drug distribution but also for avoiding potential extrahepatic complications.
Literatur
1.
Zurück zum Zitat Kemeny N, Daly J, Reichman B, et al. (1989) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107:459–565 Kemeny N, Daly J, Reichman B, et al. (1989) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107:459–565
2.
Zurück zum Zitat Rougier P, Laplanche A, Huguier M, et al. (1992) Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 40:526–530 Rougier P, Laplanche A, Huguier M, et al. (1992) Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 40:526–530
3.
Zurück zum Zitat Arai Y, Inaba Y, Takeuchi Y, et al. (1997) Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 40:526–530PubMedCrossRef Arai Y, Inaba Y, Takeuchi Y, et al. (1997) Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 40:526–530PubMedCrossRef
4.
Zurück zum Zitat Seki H, Kimura M, Yoshimura N, et al. (1998) Development of extrahepatic arterial blood supply to the liver during hepatic arterial blood supply to the liver during hepatic arterial infusion chemotherapy. Eur Radiol 8:1613–1618PubMedCrossRef Seki H, Kimura M, Yoshimura N, et al. (1998) Development of extrahepatic arterial blood supply to the liver during hepatic arterial blood supply to the liver during hepatic arterial infusion chemotherapy. Eur Radiol 8:1613–1618PubMedCrossRef
5.
Zurück zum Zitat Pozniak MA, Bebel SG, Trump DL (1991) Complications of hepatic arterial infusion chemotherapy. RadioGraphics 3:67–69 Pozniak MA, Bebel SG, Trump DL (1991) Complications of hepatic arterial infusion chemotherapy. RadioGraphics 3:67–69
6.
Zurück zum Zitat Hohn DC, Stagg RJ, Price DC, et al. (1985) Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2´-deoxyurine. J Clin Oncol 3:1257–1260PubMed Hohn DC, Stagg RJ, Price DC, et al. (1985) Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2´-deoxyurine. J Clin Oncol 3:1257–1260PubMed
7.
Zurück zum Zitat Bledin AG, Kim EE, Chuang VP, et al. (1984) Change of arterial blood flow patterns during infusion chemotherapy, as monitored by intra-arterial injected technetium 99m macroaggregated albumin. Br J Radiol 57:197–203PubMed Bledin AG, Kim EE, Chuang VP, et al. (1984) Change of arterial blood flow patterns during infusion chemotherapy, as monitored by intra-arterial injected technetium 99m macroaggregated albumin. Br J Radiol 57:197–203PubMed
8.
Zurück zum Zitat Civelek AC, Sitzmann JV, Chin BB, et al. (1993) Misperfusion of the liver during hepatic artery infusion chemotherapy: Value of preoperative angiography and post operative pump scintigraphy. Am J Roentgenol 160:865–870 Civelek AC, Sitzmann JV, Chin BB, et al. (1993) Misperfusion of the liver during hepatic artery infusion chemotherapy: Value of preoperative angiography and post operative pump scintigraphy. Am J Roentgenol 160:865–870
9.
Zurück zum Zitat Ikeda O, Kusunoki S, Nakaura T, et al. (2004) Evaluation of fusion imaging using a combined spect/ct system; assessment of drug distribustion in patients whose catheter was fixed into a brunch of the hepatic aretry. J Vasc Intervent Radiol 19:393–397 Ikeda O, Kusunoki S, Nakaura T, et al. (2004) Evaluation of fusion imaging using a combined spect/ct system; assessment of drug distribustion in patients whose catheter was fixed into a brunch of the hepatic aretry. J Vasc Intervent Radiol 19:393–397
10.
Zurück zum Zitat Seki H, Kimura M, Kamura T, et al. (1996) Hepatic perfusion abnormalities during treatment with hepatic arterial infusion chemotherapy: Value of CT arteriography using an implantable port system. J Comput Assist Tomogr 20:343–348PubMedCrossRef Seki H, Kimura M, Kamura T, et al. (1996) Hepatic perfusion abnormalities during treatment with hepatic arterial infusion chemotherapy: Value of CT arteriography using an implantable port system. J Comput Assist Tomogr 20:343–348PubMedCrossRef
11.
Zurück zum Zitat Morimoto M, Satake M, Sekiguchi R, et al. (1999) Optimal injection protocol for CT evaluation during hepatic arterial infusion chemotherapy. Invest Radiol 34:744–750PubMedCrossRef Morimoto M, Satake M, Sekiguchi R, et al. (1999) Optimal injection protocol for CT evaluation during hepatic arterial infusion chemotherapy. Invest Radiol 34:744–750PubMedCrossRef
12.
Zurück zum Zitat Krausz Y, Keidar Z, Kogant I, et al. (2003) SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 59(5):565–573CrossRef Krausz Y, Keidar Z, Kogant I, et al. (2003) SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 59(5):565–573CrossRef
13.
Zurück zum Zitat Even-Sapir E, Lerman H, Lievshitz G, et al. (2003) Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med 44(9):1413–1420PubMed Even-Sapir E, Lerman H, Lievshitz G, et al. (2003) Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med 44(9):1413–1420PubMed
14.
Zurück zum Zitat Koral KF, Dewaraja Y, Li J, et al. (2003) Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med 44(3):457–464PubMed Koral KF, Dewaraja Y, Li J, et al. (2003) Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med 44(3):457–464PubMed
15.
Zurück zum Zitat Lorenz M, Muller HH (2000) Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18:243–254PubMed Lorenz M, Muller HH (2000) Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18:243–254PubMed
16.
Zurück zum Zitat Allen-Mersh TG, Earlam S, Fordy C, et al. (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastasis. Lancet 344:1255–1260PubMed Allen-Mersh TG, Earlam S, Fordy C, et al. (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastasis. Lancet 344:1255–1260PubMed
17.
Zurück zum Zitat Valeri A, Mini E, Tonelli P, et al. (1994) Intra-arterial hepatic chemotherapy with 5-fluorouracil and 5-methyltetrahydrofolate in the treatment of unresectable liver metastases from colorectal cancer. Anticancer Res 14:2215–2219PubMed Valeri A, Mini E, Tonelli P, et al. (1994) Intra-arterial hepatic chemotherapy with 5-fluorouracil and 5-methyltetrahydrofolate in the treatment of unresectable liver metastases from colorectal cancer. Anticancer Res 14:2215–2219PubMed
18.
Zurück zum Zitat Niederhuber JE, Ensminger WD (1983) Surgical considerations in the management of hepatic neoplasia. Semin Oncol 10:135–147PubMed Niederhuber JE, Ensminger WD (1983) Surgical considerations in the management of hepatic neoplasia. Semin Oncol 10:135–147PubMed
19.
Zurück zum Zitat Huk I, Entsheff P, Prager M, et al. (1990) Patency rate of implantable devices during long-term intraarterial chemotherapy. Angiology 41:936–941PubMed Huk I, Entsheff P, Prager M, et al. (1990) Patency rate of implantable devices during long-term intraarterial chemotherapy. Angiology 41:936–941PubMed
20.
Zurück zum Zitat Seki H, Kimura M, Yoshimura N, et al. (1999) Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: Assessment of factors affecting patency of the hepatic artery. Clin Radiol 54:221–227PubMedCrossRef Seki H, Kimura M, Yoshimura N, et al. (1999) Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: Assessment of factors affecting patency of the hepatic artery. Clin Radiol 54:221–227PubMedCrossRef
21.
Zurück zum Zitat Tanaka T, Arai Y, Inaba Y, et al. (2003) Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Intervent Radiol 14:63–68 Tanaka T, Arai Y, Inaba Y, et al. (2003) Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Intervent Radiol 14:63–68
Metadaten
Titel
Comparison of Fusion Imaging Using a Combined SPECT/CT System and Intra-arterial CT: Assessment of Drug Distribution by an Implantable Port System in Patients Undergoing Hepatic Arterial Infusion Chemotherapy
verfasst von
Osamu Ikeda
Shinichiroh Kusunoki
Takeshi Nakaura
Shinya Shiraishi
Kouichi Kawanaka
Seiji Tomiguchi
Yasuyuki Yamashita
Hiroshi Takamori
Akira Chikamoto
Keiichiro Kanemitsu
Publikationsdatum
01.06.2006
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 3/2006
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-005-0268-9

Weitere Artikel der Ausgabe 3/2006

CardioVascular and Interventional Radiology 3/2006 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.